The impact of PET scanning on management of paediatric oncology patients
The impact of PET scanning on management of paediatric oncology patients
复制标题
DOI：
10.1007/s00259-004-1645-3
复制
发表时间：
2005-01-01
影响因子：
9.1
通讯作者：
O'Doherty, MJ
中科院分区：
文献类型：
--
作者：
Wegner, EA;Barrington, SF;O'Doherty, MJ
目的：关于在儿科肿瘤学中使用正电子发射断层扫描 (PET) 的信息有限。本研究的目的是回顾 PET 对 10 年来扫描的儿科患者管理的影响。方法：纳入了 165 名年龄在 11 个月至 17 岁之间的连续肿瘤患者。进行了 237 次扫描。诊断包括淋巴瘤（60例）、中枢神经系统（CNS）肿瘤（59例）、肉瘤（19例）、疑似恶变的丛状神经纤维瘤（13例）和其他肿瘤（14例）。我们向转诊临床医生发送了一份调查问卷，以确定 PET 扫描是否改变了治疗，以及 PET 扫描是否总体上被认为是有帮助的。结果：共退回 126 名患者的 189 份 (80%) 调查问卷（63 份与淋巴瘤有关，62 份与中枢神经系统肿瘤有关，30 份与肉瘤有关，16 份与丛状神经纤维瘤有关，18 份与其他肿瘤有关）。 PET 改变了 46 例 (24%) 病例的疾病管理，并为 141 例 (75%) 病例提供了帮助。 141 例（75%）的 PET 结果通过组织学、临床随访或其他检查得到验证。返回的调查问卷表明，PET 导致 20 例（32%）淋巴瘤病例、9 例（15%）中枢神经系统肿瘤、4 例（13%）肉瘤、9 例（56%）丛状神经纤维瘤和 4 例（22%）其他肿瘤病例的治疗发生变化。 PET 被认为对 47 例（75%）淋巴瘤病例、48 例（77%）中枢神经系统肿瘤、24 例（80%）肉瘤、11 例（69%）神经纤维瘤和 11 例（61%）其他肿瘤病例有帮助。 PET 结果在 44 例（70%）淋巴瘤病例、53 例（85%）中枢神经系统肿瘤、21 例（70%）肉瘤、12 例（75%）神经纤维瘤和 11 例（61%）其他肿瘤病例中得到验证。结论：儿童癌症 PET 成像准确且实用。 PET 改变了治疗方法，并被认为对大量患者有帮助（无论是否改变治疗方法），其结果与针对成人肿瘤人群公布的数据相当。
Purpose: Limited information is available on the use of positron emission tomography (PET) in paediatric oncology. The aim of this study was to review the impact of PET on the management of paediatric patients scanned over a 10-year period.Methods: One hundred and sixty-five consecutive oncology patients aged 11 months to 17 years were included. Two hundred and thirty-seven scans were performed. Diagnoses included lymphoma (60 patients), central nervous system (CNS) tumour (59), sarcoma (19), plexiform neurofibroma with suspected malignant change (13) and other tumours (14). A questionnaire was sent to the referring clinician to determine whether the PET scan had altered management and whether overall the PET scan was thought to be helpful.Results: One hundred and eighty-nine (80%) questionnaires for 126 patients were returned (63 relating to lymphoma, 62 to CNS tumours, 30 to sarcoma, 16 to plexiform neurofibroma and 18 to other tumours). PET changed disease management in 46 (24%) cases and was helpful in 141 (75%) cases. PET findings were verified by histology, clinical follow-up or other investigations in 141 cases (75%). The returned questionnaires indicated that PET had led to a management change in 20 (32%) lymphoma cases, nine (15%) CNS tumours, four (13%) sarcomas, nine (56%) plexiform neurofibromas and four (22%) cases of other tumours. PET was thought to be helpful in 47 (75%) lymphoma cases, 48 (77%) CNS tumours, 24 (80%) sarcomas, 11 (69%) neurofibromas and 11 (61%) cases of other tumours. PET findings were verified in 44 (70%) lymphoma cases, 53 (85%) CNS tumours, 21 (70%) sarcomas, 12 (75%) neurofibromas and 11 (61%) other tumour cases.Conclusion: PET imaging of children with cancer is accurate and practical. PET alters management and is deemed helpful (with or without management change) in a significant number of patients, and the results are comparable with the figures published for the adult oncology population.